Summary: Forecasting pharmacokinetics (PK) for individual patients is a fundamental problem in clinical pharmacology. One key challenge is that PK models constructed using data from one dosing regimen must predict PK data for different dosing regimen(s). We propose a deep learning approach based on neural ordinary differential equations (neural-ODE) and tested its generalizability against a variety of alternative models. Specifically, we used the PK data from two different treatment regimens of trastuzumab emtansine. The models performed similarly when the training and the test sets come from the same dosing regimen. However, for predicting a new treatment regimen, the neural-ODE model showed substantially better performance. To date, neura...
Abstract The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is ...
Forecasting healthcare time series is crucial for early detection of adverse outcomes and for patien...
Pharmacometrics modeling encompasses both pharmacokinetics (PK) and pharmacodynamics (PD) data to qu...
Nonlinear mixed effect (NLME) models are the gold standard for the analysis of patient response foll...
Modeling a system's temporal behaviour in reaction to external stimuli is a fundamental problem in m...
While tumor dynamic modeling has been widely applied to support the development of oncology drugs, t...
Nonlinear Mixed effect models are often used to describe population pharmacokinetics (PK) and Pharma...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Abstract Both machine learning and physiologically-based pharmacokinetic models are becoming essenti...
Artificial Intelligence Lab, Department of MIS, University of ArizonaThis research examined the appl...
Abstract We developed a method to apply artificial neural networks (ANNs) for predicting time‐series...
The application of machine learning (ML) has shown promising results in precision medicine due to it...
This work presents a pharmacodynamic population analysis in chronic renal failure patients using Art...
Early pharmacokinetic optimisation is a key principle in drug discovery and development. Modeling ab...
Abstract The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is ...
Forecasting healthcare time series is crucial for early detection of adverse outcomes and for patien...
Pharmacometrics modeling encompasses both pharmacokinetics (PK) and pharmacodynamics (PD) data to qu...
Nonlinear mixed effect (NLME) models are the gold standard for the analysis of patient response foll...
Modeling a system's temporal behaviour in reaction to external stimuli is a fundamental problem in m...
While tumor dynamic modeling has been widely applied to support the development of oncology drugs, t...
Nonlinear Mixed effect models are often used to describe population pharmacokinetics (PK) and Pharma...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Abstract Both machine learning and physiologically-based pharmacokinetic models are becoming essenti...
Artificial Intelligence Lab, Department of MIS, University of ArizonaThis research examined the appl...
Abstract We developed a method to apply artificial neural networks (ANNs) for predicting time‐series...
The application of machine learning (ML) has shown promising results in precision medicine due to it...
This work presents a pharmacodynamic population analysis in chronic renal failure patients using Art...
Early pharmacokinetic optimisation is a key principle in drug discovery and development. Modeling ab...
Abstract The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is ...
Forecasting healthcare time series is crucial for early detection of adverse outcomes and for patien...
Pharmacometrics modeling encompasses both pharmacokinetics (PK) and pharmacodynamics (PD) data to qu...